Science Current Events | Science News | Brightsurf.com
 

Combining therapies can improve survival for early-stage breast cancer patients

April 04, 2007
Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression—treatment to stop the ovaries from functioning—did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.

Survival rates improve for patients with early-stage breast cancer who receive a single method of treatment—either tamoxifen, ovarian suppression, or chemotherapy. Two international studies by the Adjuvant Breast Cancer Trials Collaborative Group were designed to test whether combining these treatments would provide additional benefits.

Judith Bliss of The Institute of Cancer Research in Sutton, England, and colleagues conducted two randomized controlled phase III clinical trials of 3,854 women with early-stage breast cancer, all of whom were treated with tamoxifen for five years. In the first trial, nearly half of the 2,144 premenopausal women were randomly assigned to receive ovarian suppression, and the other half did not. Some also received chemotherapy. In the second trial, 1,991 patients were randomly assigned to receive chemotherapy, and the other half were not. Some premenopausal women also had ovarian suppression.

The researchers found that chemotherapy treatment resulted in a modest yet sustained improvement in both relapse-free and overall survival. These improvements were especially strong in women younger than 50 years and in premenopausal women who did not receive ovarian suppression.

They also found that neither relapse-free survival nor overall survival was affected by the addition of ovarian suppression. However, the results indicate a possible benefit of ovarian suppression when given along side tamoxifen for a small group of women younger than 40 years who have ER-positive tumors (tumors that need estrogen to grow), especially when they are not receiving chemotherapy. The researchers called for further research into this group of breast cancer patients.

"Relapse-free survival benefits emerged early and were maintained, whereas overall survival benefits did not emerge for at least 5 years, reinforcing the need for long-term follow-up in chemotherapy trials," the authors write. The trials add "to the limited data available on the effects of combining long-term tamoxifen, chemotherapy, and ovarian ablation of suppression."

In an accompanying editorial, Kathleen Pritchard, M.D., of Toronto Sunnybrook Regional Cancer Centre, describes how the trial could have found more interesting results if there had been more data on patients' ER status. "Most of all, however, these studies stress the importance of establishing processes to ensure the availability of archived tumor specimens for all randomized adjuvant trials. The era in which such large important trials should be carried out without the archived correlational tumor samples is over."

Journal of the National Cancer Institute


Related Tamoxifen Current Events and Tamoxifen News Articles


Scientists restore hearing in noise-deafened mice, pointing way to new therapies
Scientists have restored the hearing of mice partly deafened by noise, using advanced tools to boost the production of a key protein in their ears.

Subsidies help breast cancer patients adhere to hormone therapy
A federal prescription-subsidy program for low-income women on Medicare significantly improved their adherence to hormone therapy to prevent the recurrence of breast cancer after surgery.

Scientists discover a new role for estrogen in the pathology of breast cancer
Scientists have discovered a previously unknown mechanism by which estrogen prepares cells to divide, grow and, in the case of estrogen-positive breast cancers, resist cancer drugs.

The 'Angelina Effect' was not only immediate, but also long-lasting
Referrals for genetic counselling and testing for breast cancer risk more than doubled across the UK after actress Angelina Jolie announced in May last year that she tested positive for a BRCA1 gene mutation and underwent a double mastectomy.

WIH Researchers Examine Role of Hormone in Patient Responses to Ovarian Cancer Treatment
Researchers at Women & Infants Hospital of Rhode Island recently published the results of an investigation into how we might better tailor therapy for ovarian cancer.

Exposure to dim light at night may make breast cancers resistant to tamoxifen
For rats bearing human breast tumors, exposure to dim light at night made the tumors resistant to the breast cancer drug tamoxifen, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

Total darkness at night is key to success of breast cancer therapy -- Tulane study
Exposure to light at night, which shuts off nighttime production of the hormone melatonin, renders breast cancer completely resistant to tamoxifen, a widely used breast cancer drug, says a new study by Tulane University School of Medicine cancer researchers.

What if hormones aren't fuel for the fire after all?
It's no wonder that breast cancer ranks highest among women's health concerns. Over 235,000 cases of breast cancer are diagnosed annually in the United States, with almost 40,000 deaths attributable to the disease.

New skin gel fights breast cancer without blood clot risk
A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects that deter some women from taking it.

Study Shows Anti-Androgen Receptor Therapy for Triple-Negative Breast Cancer May Benefit More Than Just High-Androgen Receptor Tumors
Triple-negative breast cancers do not benefit from the targeted therapies that have greatly improved the survival of patients with other subtypes of breast cancer.
More Tamoxifen Current Events and Tamoxifen News Articles

Tamoxifen and Breast Cancer (Yale Fastback Series)

Tamoxifen and Breast Cancer (Yale Fastback Series)
by Michael W. DeGregorio (Author), Valerie J. Wiebe (Author)


A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.

STRIPPED: Cancer, Culture, and the Cloud of Unknowing

STRIPPED: Cancer, Culture, and the Cloud of Unknowing
by Heather King (Author)


I'm a lawyer turned writer, a Catholic convert, and a sober alcoholic. In 2000, I was diagnosed with invasive breast cancer. The good news: a small tumor; the least advanced stage. Still, doctors recommended surgery, radiation, high-dose chemo, and five years of the aggressive hormone drug Tamoxifen.

Terrified of dying, yet determined to steer my own course, I began researching. I found that chemo could kill, radiation could cause secondary cancers, Tamoxifen had severe side effects, and long-term studies on any of those treatments was virtually nil.

STRIPPED is a memoir about coming to the decision to have the tumor surgically removed--and to forego all further treatment. To love this world with all my heart, even as I know I'll be leaving it one day, is to dwell at the...

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)

Tamoxifen: Pioneering Medicine in Breast Cancer (Milestones in Drug Therapy)
by Philipp Y. Maximov (Author), Russell E. McDaniel (Author), V. Craig Jordan (Author)


Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the...

Keeping You Abreast of My Developments: In the trenches with breast cancer

Keeping You Abreast of My Developments: In the trenches with breast cancer


I wrote this short book to document my journey with breast cancer. I also want to inform cancer patients’ loved ones so they know what breast cancer patients go through and can better help the patients in their battle with cancer. I describe procedures and include my thoughts and fears as well as links concerning valuable information about cancer and research to help readers understand what happens when patients battle breast cancer. I include links for readers to pursue more information.
I hope the images I chose for the front and back of my book, as well as within my book, show that cancer will not define, depress, or defeat me. It will not take away my joy of living or sense of humor, but it will make me embrace life more fully, forgive more often, and love more deeply.
Long-Term Tamoxifen Treatment

Long-Term Tamoxifen Treatment
by V. Craig Jordan (Author)


During the past twenty years tamoxifen has become the most widely prescribed and most successful drug used in the treatment of breast cancer.  In this volume, editor V. Craig Jordan provides articles that trace the development, pharmacology, and clinical research surrounding this drug which, by the year 2000, could be used to treat as many as one million women annually.
    Drawing from research conducted by specialists in the United States, the United Kingdom, and Italy, the series of articles describes the clinical testing of tamoxifen, highlighting the benefits.  Studies show that tamoxifen lowers cholesterol and can potentially protect women against osteoporosis and fatal coronary heart disease.  Equally important is a discussion of side effects and possible drug interactions...

Dr. Susan Love's Breast Book, 5th Edition (A Merloyd Lawrence Book)

Dr. Susan Love's Breast Book, 5th Edition (A Merloyd Lawrence Book)
by Susan M. Love MD (Author), Karen Lindsey (Contributor)


Dr. Susan Love's Breast Book has long been the bible for the newly diagnosed. In this completely revised fifth edition, it also becomes a guide for those at risk of getting breast cancer, survivors interested in the consequences of their treatment, and anyone who wants to understand the new research about how the local environment influences the manifestations and treatments of many different kinds of breast cancer. Major advances being made in genetic research today mean that prevention and treatment can work not only to get rid of mutated cells (through chemo or surgery), but also to change the environment around the cells (through hormone therapy, exercise, and stress reduction). Among other promising developments discussed are advances in imaging, recognition of breast density as a...

Tamoxifen: Beyond the Antiestrogen

Tamoxifen: Beyond the Antiestrogen
by Birkhäuser


Tamoxifen is a drug used as an antisteroidal substance. This work looks at the effects of the Tamoxifen beyond the scope of simple oestrogen antagonism. It examines the numerous "side effects" of the drug and looks at the complexity of its actions.

  Early results: topical tamoxifen looks promising for DCIS.(GYNECOLOGY)(Clinical report): An article from: OB GYN News
by Elizabeth Mechcate (Author)




The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change

The Wisdom of Menopause (Revised Edition): Creating Physical and Emotional Health During the Change
by Christiane Northrup M.D. (Author)


Dr. Christiane Northrup’s #1 New York Times bestseller The Wisdom of Menopause has inspired more than a million women with a dramatically new vision of midlife—and will continue to do so for generations to come. As Dr. Northrup has championed, the “change” is not simply a collection of physical symptoms to be “fixed,” but a mind-body revolution that brings the greatest opportunity for growth since adolescence. The choices a woman makes now—from the quality of her relationships to the quality of her diet—have the power to secure vibrant health and well-being for the rest of her life.

Now completely revised, this groundbreaking classic draws on the current research and medical advances in women’s health, and includes
 
• a new section on sex after 50—and...

Tamoxifen nel trattamento del carcinoma mammario: Studio dei fattori predittivi di risposta (Italian Edition)

Tamoxifen nel trattamento del carcinoma mammario: Studio dei fattori predittivi di risposta (Italian Edition)
by Laura Bertolaso (Author)


Il tamoxifen è un farmaco ampiamente usato per il trattamento e la prevenzione del più frequente istotipo di tumore mammario, quello positivo per i recettori degli estrogeni. Nonostante i notevoli successi nella pratica clinica derivanti dall'impiego di tale farmaco, essi non riguardano ancora la totalità delle pazienti. Questo libro espone i promettenti seppur preliminari risultati di uno studio iniziato nel 2010 volto ad analizzare sperimentalmente i fattori molecolari e genetici a potenziale carattere predittivo nella determinazione della risposta terapeutica.

© 2014 BrightSurf.com